Skip to content
HowShorted

Dianthus Therapeutics, Inc. short interest in 2020

In 2020, Dianthus Therapeutics, Inc.'s disclosed short interest ran from 5.06% of shares outstanding on 15 Jan 2020 to 3.88% on 31 Dec 2020, a change of -1.18 percentage points. The year's high was 5.47% on 13 Mar 2020 and its low 2.29% on 29 May 2020, averaging 3.75% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.35 days on 14 Feb 2020. Full history: Dianthus Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Dianthus Therapeutics, Inc. in 2020

2020 in figures

Start of year
5.06% (15 Jan 2020)
End of year
3.88% (31 Dec 2020)
Change
-1.18 pp
High
5.47% (13 Mar 2020)
Low
2.29% (29 May 2020)
Average
3.75%
Highest days to cover
26.35 (14 Feb 2020)
SEC filings marked
9

Every report in 2020

Dianthus Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20205.06%19.97results (8-K)
31 Jan 20205.15%21.94
14 Feb 20205.00%26.35
28 Feb 20205.26%17.18
13 Mar 20205.47%22.0510-K filed, results (8-K)
31 Mar 20203.64%4.96
15 Apr 20202.96%5.76
30 Apr 20203.04%8.62
15 May 20203.22%8.5110-Q filed, results (8-K)
29 May 20202.29%7.23
15 Jun 20202.59%6.65
30 Jun 20203.69%2.62
15 Jul 20203.48%2.39
31 Jul 20203.21%6.43
14 Aug 20203.07%7.3410-Q filed, results (8-K)
31 Aug 20203.25%7.87
15 Sep 20203.38%7.08
30 Sep 20203.32%7.98
15 Oct 20203.33%13.79
30 Oct 20203.87%8.06
13 Nov 20203.86%11.6510-Q filed, results (8-K)
30 Nov 20203.95%17.06
15 Dec 20203.96%18.86
31 Dec 20203.88%10.05

See also: Dianthus Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.